
Topic
Post-Approval Changes
Supplements, variations, PACMPs, comparability protocols, and post-approval CMC change management across FDA, EMA, and global markets.

Manufacturing· May 22, 2026 · 10 min read
By Ran Chen#CMC#FDA#Regulatory

Manufacturing· May 22, 2026 · 13 min read
API supplier change control: DMF letter-of-authorization and notification traps

Manufacturing· May 22, 2026 · 10 min read
CDMO quality agreement red flags that become FDA inspection findings
By Ran Chen#Manufacturing Capacity#CMC#FDA Approval

Manufacturing· May 22, 2026 · 14 min read
CMC-only complete response letters: how commercial teams should read the risk
By Ran Chen#Manufacturing Capacity#CMC#FDA Approval

Manufacturing· May 22, 2026 · 12 min read
eCTD Module 3 lifecycle hygiene after multiple post-approval supplements
By Ran Chen#CMC#Post-Approval Changes#ICH

Manufacturing· May 22, 2026 · 12 min read
Global CMC change classification mismatch between FDA, EMA, and non-ICH markets
By Ran Chen#CMC#Post-Approval Changes#ICH

Manufacturing· May 22, 2026 · 14 min read
ICH Q12 established conditions: how to decide what really belongs in the regulatory submission
By Ran Chen#CMC#ICH#Regulatory

Policy· May 22, 2026 · 11 min read
Labeling supplement timing after a new indication approval and why launch teams miss it

Manufacturing· May 22, 2026 · 11 min read
PACMP strategy for a planned biologic manufacturing site change

Manufacturing· May 22, 2026 · 12 min read